Clinical Trial Update: Safety of and Immune Response to DEN4 Vaccine Component Candidate for Dengue Virus [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating safety and immune response to a DEN4 dengue vaccine component candidate; the study has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dengue Hemorrhagic Fever
• Dengue Shock Syndrome

Drugs mentioned

• DEN4 vaccine component candidate for dengue virus (DEN4 vaccine component)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Dengue Shock Syndrome, Dengue Hemorrhagic Fever | Phase 1 | Status: COMPLETED